293480.Ks

The company maintains a relatively strong liquidity position, with a current ratio of 1.84, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, its free cash flow is negative at -20,198,592,090 KRW, which suggests that the company is spending more on capital expenditures than it is generating in operating cash flow. The price-to-book ratio of 0.56 indicates that the company's market value is trading at a discount to its book value, which may reflect market skepticism about its future earnings potential or asset quality.

In terms of profitability, the company's return on equity (ROE) is 2.8%, and its return on assets (ROA) is 2.1%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. These figures suggest that the company is not generating particularly high returns relative to its equity and asset base. The company's gross profit margin is 60.5%, which is in line with industry norms, but its operating margin of 10.7% is relatively modest, indicating that the company may be facing competitive pressures or cost inefficiencies.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, and there is no indication of geographic diversification in the provided data. This lack of diversification could expose the company to higher risk if demand in its primary market or product line declines. The company's revenue for the latest period is 239,503,892,660 KRW, and while there is no specific growth trajectory provided, the negative free cash flow and modest operating margin suggest that the company may be investing heavily in its operations or facing margin compression.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key liquidity flag is that the company's net cash position is negative after accounting for total debt, which could limit its ability to fund operations or make strategic investments without external financing. The company's debt-to-equity ratio of 0.19 is relatively low, indicating a conservative capital structure, but the presence of long-term debt at 58,719,602,310 KRW suggests that the company is not entirely debt-free.

There are no specific recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial position. However, the negative free cash flow and modest operating margin may signal underlying operational challenges that warrant further investigation.